Mark A. Velleca - Sep 20, 2022 Form 4 Insider Report for G1 Therapeutics, Inc. (GTHX)

Role
Director
Signature
/s/ James Stillman Hanson, attorney-in-fact
Stock symbol
GTHX
Transactions as of
Sep 20, 2022
Transactions value $
-$262,244
Form type
4
Date filed
9/22/2022, 04:40 PM
Previous filing
Sep 19, 2022
Next filing
Oct 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Options Exercise $7.8K +20K +17.24% $0.39 136K Sep 20, 2022 Direct
transaction GTHX Common Stock Sale -$270K -20K -14.71% $13.50* 116K Sep 20, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Option (Right to Buy) Options Exercise $0 -20K -21.67% $0.00 72.3K Sep 20, 2022 Common Stock 20K $0.39 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2 The price represents the weighted average price with a low of $13.12 and a high of $13.92. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth.
F3 All shares underlying this option have vested.